Biospective and Target ALS have partnered to establish this collaborative platform to allow scientific researchers around the world to easily share their innovative work related to ALS. The "Image Interactives" on this Initiative allow the community to explore detailed high-resolution microscopy images from a broad range of modalities (e.g. brightfield, fluorescence, confocal, super-resolution, electron microscopy) from cell models, animal models, and humans, accompanied by narrated content, annotations, and complementary data provided by the authors.
This Open Science Platform is freely accessible to everyone. If you would like to contribute your original research to this Initiative, please contact us.
Highlights
This month's featured "Image Interactives" from the ALS Research Community
Quantitative Image Analysis of NMJ Denervation in the rNLS8 TDP-43 Model
Alexa Brown, Ph.D. and Barry J. Bedell, M.D., Ph.D. Biospective Inc., Montreal, CanadaUpdated on: Sep 18, 2025Quantitative analysis of fluorescence images reveals progressive NMJ denervation in the rNLS8 TDP-43 mouse model of ALS.
Confocal Imaging of Neuron-Microglia Interactions in ALS
Jason Bell, M.D., Theo Strade, and Emily Kang, Ph.D. University of Pennsylvania, Center for NeuroinflammationUpdated on: Sep 17, 2025Confocal images reveal altered neuron-microglia interactions in ALS, highlighting changes in cellular proximity and morphology.
Cryo-EM Imaging of Mitochondria in Motor Neurons from ALS Patients
Hanna Patel, M.D., Ph.D. and Jordan Briarhold, M.D., Ph.D. Seoul National University College of Medicine, Department of Anatomy and Cell BiologyUpdated on: Aug 10, 2025Cryo-EM imaging of ALS motor neurons reveals structural changes in mitochondria associated with disease-related cellular abnormalities.
High Resolution Imaging of ASC Specks in Motor Cortex of ALS Patients
Elena V. Grason, Ph.D. and Matteo Krall, M.D., Ph.D. University of Washington, Department of NeurologyUpdated on: Jul 09, 2025High-resolution imaging of ALS motor cortex shows ASC speck localization patterns associated with neuroinflammatory features of disease.
Toxic Loss & Gain of Function in a New TDP-43ΔNLS ALS Mouse Model
Alexa Brown, Ph.D. and Barry J. Bedell, M.D., Ph.D. Biospective Inc., Montreal, CanadaUpdated on: Jul 01, 2025Microscopy imaging reveals TDP-43 pathology, early motor changes, neurodegeneration, and mitochondrial alterations in a TDP-43ΔNLS ALS model.
Microglial Morphology Analysis in Spinal Cords from C9orf72 ALS Patients
Tamara Graveson, M.D., Ph.D. and Philip Ramos, Ph.D. RIKEN Center for Brain Science, Wako, JapanUpdated on: Jun 24, 2025Imaging and morphometric analysis of spinal cord tissue from C9orf72 ALS patients reveal changes in microglial morphology and distribution.
Related Content
Up-to-date information and best practices related to microscopy and ALS research.
ALS Mouse Models for Drug Development
A guide to the most effective use of research animal models (mouse & rat models) of Amyotrophic Lateral Sclerosis (ALS) for preclinical testing of therapeutics.
TDP-43 ΔNLS (rNLS8) Mice for ALS Drug Development
This resource provides information about the use of the ΔNLS (deltaNLS, hTDP-43ΔNLS, hTDP-43DeltaNLS, dNLS, TDP43 NLS, rNLS8) TDP-43 transgenic mouse model of ALS for preclinical therapeutic studies.
ALS Mouse Models & Spinal Motor Neurons
An overview of the involvement of spinal motor neurons in disease progression in mouse models of Amyotrophic Lateral Sclerosis (ALS).
Microglia Morphology in ALS, Alzheimer's Disease & Parkinson's Disease
An overview of microglial morphological analysis and the applications to neurodegenerative disease research and drug discovery & development.
About Biospective
Biospective Inc. is the leading Preclinical Neuroscience CRO specializing in cell and animal models of neurological diseases. Biospective focuses on providing a broad range of research services leveraging the best available models of ALS, Alzheimer’s Disease, Multiple Sclerosis, Parkinson's Disease, and Tauopathies.
About Target ALS
Founded in 2013, Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Target ALS has revolutionized ALS research through its landmark Innovation Ecosystem model, fostering unprecedented scientific collaboration between academia and the pharmaceutical/biotech industry.
